Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need. The Company is currently sponsoring a multi‑center Phase II clinical trial for its lead product ATIR™ and is collaborating with with renowned centers in Europe and North America.
December 5, 2013Kiadis Pharma participates in haploidentical transplantation 2013 Forum
November 18, 2013Kiadis Pharma provides positive update on its Phase II clinical program with blood cancer treatment ATIR™
October 7, 2013Kiadis Pharma secures manufacturing services agreement for its Phase II clinical program with blood cancer treatment ATIR™ with the German Red Cross Blood Donor Service
September 11, 2013Kiadis Pharma completes five-year follow-up of its Phase I/II clinical study with blood cancer product ATIR™ and study meets primary objective
July 23, 2013Kiadis Pharma to receive GMP manufacturing license and GMP certificate
June 26, 2013Kiadis Pharma awarded a EUR 3 million innovation credit from the Dutch Government for Phase II clinical development program
The Fact Sheet provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development. Click to download the PDF.
Video: five‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range. Download press release